Treatment with cisplatin increases TGF-β production by NSCLC cells, which in turn activates CAFs, resulting in an increase of IL-6 and ultimately contributes to enhancing TGF-β-induced EMT in NSCLC. Here, TGFB1 is linked to non-small cell lung carcinoma.